We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Recommends Endpoint for Hormone Analogues for Prostate Cancer
FDA Recommends Endpoint for Hormone Analogues for Prostate Cancer
Testerone level should be used as a surrogate endpoint in phase 3 trials of gonadotropin-releasing hormone (GnRH) analogues for treating advanced prostate cancer, the FDA says in a new draft guidance.